Breathe Well Live Well
Daily Mail |
Asthma–food allergy combination linked to poor outcomes
medwireNews medwireNews: US research in a group of inner-city school children with asthma shows that those with food allergies experience greater asthma-related morbidity, use more healthcare resources, and have greater lung function impairment than those without. A victory for Florida students with food allergies |
View full post on asthma – Google News
Condition: Asthma
Interventions: Drug: FP/SAL; Drug: BDP/FOR
Sponsors: Research in Real-Life Ltd; Research in Real-Life Ltd; Chiesi Farmaceutici S.p.A.
Completed – verified July 2013
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Condition: Asthma
Interventions: Drug: CHF1535 pMDI + AC Plus; Drug: BDP + AC Plus; Drug: Formoterol + AC Plus
Sponsors: Chiesi Farmaceutici S.p.A.; Chiesi Farmaceutici S.p.A.
Completed – verified May 2013
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Condition: Asthma
Interventions: Drug: CHF1535 pMDI + AC Plus; Drug: BDP and Formoterol + AC Plus
Sponsors: Chiesi Farmaceutici S.p.A.; Chiesi Farmaceutici S.p.A.
Completed – verified April 2013
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Condition: Asthma
Interventions: Drug: FF/VI 100/25 mcg; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting – verified April 2013
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
|
Childhood asthma tied to combination of genes and wheezing illness
EurekAlert (press release) About 90 percent of children with two copies of a common genetic variation and who wheezed when they caught a cold early in life went on to develop asthma by age 6, according to a study to be published March 28 by the New England Journal of Medicine. |
View full post on asthma – Google News
|
Combination of genes, cold symptoms may trigger asthma in children
WGNtv.com A combination of genes and a symptom of the common cold can put kids at increased risk for asthma. It's an association local researchers at the University of Chicago have confirmed and it may help lead to therapies to prevent the most common chronic … |
View full post on asthma – Google News
 Packaging World |
Aptar Pharma dose indicator selected for new asthma combination therapy
Packaging World It is indicated for the maintenance treatment of asthma in patients aged 12 years and over, and in adults whose symptoms are not adequately controlled on an ICS and an as-required inhaled short-acting beta2-agonist (SABA), and in those patients who are … |
View full post on asthma – Google News
|
Aptar Pharma dose indicator selected for new asthma combination therapy
Healthcare Packaging It is indicated for the maintenance treatment of asthma in patients aged 12 years and over (50/5?g and 125/5?g strengths), and in adults (250/10?g strength) whose symptoms are not adequately controlled on an ICS and an as-required inhaled short-acting … |
View full post on asthma – Google News
Onset of Bronchodilation with Fluticasone/Formoterol Combination Versus Fluticasone/Salmeterol in an Open-Label, Randomized Study.
Adv Ther. 2012 Oct 17;
Authors: Aalbers R, Brusselle G, McIver T, Grothe B, Bodzenta-Lukaszyk A
Abstract
INTRODUCTION: The inhaled corticosteroid, fluticasone propionate (fluticasone), and the long-acting beta(2)-agonist, formoterol fumarate (formoterol), have been combined in a single aerosol inhaler (fluticasone/formoterol). In a randomized, open-label study, fluticasone/formoterol showed similar efficacy to fluticasone/salmeterol after 12 weeks of treatment. This post-hoc analysis compared the onset of bronchodilation with the two treatments. METHODS: Adults with mild-to-moderate-severe persistent asthma were randomized to fluticasone/formoterol (100/10 or 250/10 ?g twice daily [b.i.d.]) or fluticasone/salmeterol (100/50 or 250/50 ?g b.i.d.) for 12 weeks. The onset of bronchodilation (the first post-dose time point at which the forced expiratory volume in 1 second [FEV(1)] was ?12% greater than the pre-dose value), responder rates (the proportion of patients achieving bronchodilation), and changes in FEV(1) were assessed at days 0 (baseline) and 84. RESULTS: Fluticasone/formoterol (n = 101) provided more rapid onset of bronchodilation than fluticasone/salmeterol (n = 101) over the first 120 min post-dose on days 0 (hazard ratio [HR] = 1.47 [95% CI 1.05-2.05]) and 84 (HR = 1.77 [95% CI 1.14-2.73]). The odds of a patient achieving bronchodilation within 5 min of dosing were almost four-times higher with fluticasone/formoterol than with fluticasone/salmeterol on day 0 (odds ratio [OR] = 3.97 [95% CI 1.96-8.03]) and almost 10-times higher on day 84 (OR = 9.58 [95% CI 2.14-42.90]); the odds of achieving bronchodilation within 120 min post-dose were approximately twofold higher with fluticasone/formoterol on both days. The overall percentage increase in least-squares (LS) mean FEV1 during the 120-min post-dose period was significantly greater with fluticasone/formoterol than fluticasone/salmeterol on days 0 (LS mean treatment difference: 4.70% [95% CI 1.57-7.83]; P = 0.003) and 84 (2.79% [95% CI 0.65-4.93]; P = 0.011). CONCLUSION: These analyses showed that fluticasone/formoterol provided a faster onset of bronchodilation than fluticasone/salmeterol, which was maintained over 12 weeks of treatment. This benefit may facilitate treatment adherence among patients with asthma.
PMID: 23081745 [PubMed – as supplied by publisher]
View full post on pubmed: asthma